Literature DB >> 21694643

Organ dysfunction and muscular disability in myotonic dystrophy type 1.

Pierre Kaminsky1, Mathias Poussel, Lelia Pruna, Joëlle Deibener, Bruno Chenuel, Béatrice Brembilla-Perrot.   

Abstract

Myotonic dystrophy type 1 (DM1) is a multisystemic disorder characterized by muscle weakness and multiple organ impairment, especially the eyes, lung, and heart. We conducted the current study to analyze the prevalence and intercorrelation among these disorders and their respective relationships with muscular disability. We assessed medical history, anthropometric data, lung volumes, arterial and venous blood samples, surface 12-lead electrocardiogram, echocardiography, ophthalmologic examination, and muscular impairment rating scale (MIRS) in 106 patients (48 male and 58 female) with DM1, aged 43.7 ± 12.8 years. Obesity, hypertriglyceridemia, and diabetes were found in respectively 25.6%, 47.6%, and 17.1% of patients. Disabling cataract was found in 43.4%, and was independently predicted by age and MIRS. Restrictive lung disease was noted in 34%, and was predicted by MIRS, CTG repeat expansion, and body mass index. Conduction disorders were found in 30.2% of patients and were predicted by left ventricular ejection fraction, MIRS, and CTG repeat expansion.We found significant relationships between cataract, restrictive lung disease, and conduction disorders: patients with cataract and those with conduction disorders exhibited more severe restrictive lung disease than the other patients. Conversely, the relative risk of restrictive lung disease was 2.42 (1% confidence interval [CI], 1.06-5.51) in patients with cataract and 2.54 (1% CI, 1.26-5.07) in patients with conduction disorders. Multivariate analysis revealed that MIRS was the only independent predictor for conduction disorders and restrictive lung disease. MIRS ≥3 and MIRS ≥4 were the best simple cutoff values to predict, respectively, lung and cardiac involvements.To conclude, muscular disability, ophthalmologic, and cardiac and pulmonary involvement are strongly correlated. Particular attention should be given to these entities in patients with distal or proximal muscular weakness.

Entities:  

Mesh:

Year:  2011        PMID: 21694643     DOI: 10.1097/MD.0b013e318226046b

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  11 in total

1.  Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases.

Authors:  Jean-Pierre Bouchard; Louise Cossette; Guillaume Bassez; Jack Puymirat
Journal:  J Neurol       Date:  2014-11-08       Impact factor: 4.849

2.  Genetics correlates with lung function and nocturnal ventilation in myotonic dystrophy.

Authors:  Regina Monteiro; João Bento; Miguel R Gonçalves; Tiago Pinto; João Carlos Winck
Journal:  Sleep Breath       Date:  2013-01-15       Impact factor: 2.816

Review 3.  Diagnosis of muscle diseases presenting with early respiratory failure.

Authors:  Gerald Pfeffer; Marcus Povitz; G John Gibson; Patrick F Chinnery
Journal:  J Neurol       Date:  2014-11-07       Impact factor: 4.849

4.  Muscular dystrophies at different ages: metabolic and endocrine alterations.

Authors:  Oriana Del Rocío Cruz Guzmán; Ana Laura Chávez García; Maricela Rodríguez-Cruz
Journal:  Int J Endocrinol       Date:  2012-06-03       Impact factor: 3.257

Review 5.  Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy.

Authors:  Marie-Laure Caillet-Boudin; Francisco-Jose Fernandez-Gomez; Hélène Tran; Claire-Marie Dhaenens; Luc Buee; Nicolas Sergeant
Journal:  Front Mol Neurosci       Date:  2014-01-09       Impact factor: 5.639

6.  Elevated plasma levels of cardiac troponin-I predict left ventricular systolic dysfunction in patients with myotonic dystrophy type 1: A multicentre cohort follow-up study.

Authors:  Mark J Hamilton; Yvonne Robb; Sarah Cumming; Helen Gregory; Alexis Duncan; Monika Rahman; Anne McKeown; Catherine McWilliam; John Dean; Alison Wilcox; Maria E Farrugia; Anneli Cooper; Josephine McGhie; Berit Adam; Richard Petty; Cheryl Longman; Iain Findlay; Alan Japp; Darren G Monckton; Martin A Denvir
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

7.  Structural myocardial involvement in adult patients with type 1 myotonic dystrophy.

Authors:  Upinder K Dhand; Faisal Raja; Kul Aggarwal
Journal:  Neurol Int       Date:  2013-03-21

8.  Diabetes, metformin and cancer risk in myotonic dystrophy type I.

Authors:  Rotana Alsaggaf; Ruth M Pfeiffer; Youjin Wang; Diane Marie M St George; Min Zhan; Kathryn R Wagner; Sania Amr; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2019-12-19       Impact factor: 7.316

9.  Orthopaedic Disorders in Myotonic Dystrophy Type 1: descriptive clinical study of 21 patients.

Authors:  Lisa Schilling; Raimund Forst; Jürgen Forst; Albert Fujak
Journal:  BMC Musculoskelet Disord       Date:  2013-12-01       Impact factor: 2.362

10.  Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational Study.

Authors:  Celine Dogan; Marie De Antonio; Dalil Hamroun; Hugo Varet; Marianne Fabbro; Felix Rougier; Khadija Amarof; Marie-Christine Arne Bes; Anne-Laure Bedat-Millet; Anthony Behin; Remi Bellance; Françoise Bouhour; Celia Boutte; François Boyer; Emmanuelle Campana-Salort; Françoise Chapon; Pascal Cintas; Claude Desnuelle; Romain Deschamps; Valerie Drouin-Garraud; Xavier Ferrer; Helene Gervais-Bernard; Karima Ghorab; Pascal Laforet; Armelle Magot; Laurent Magy; Dominique Menard; Marie-Christine Minot; Aleksandra Nadaj-Pakleza; Sybille Pellieux; Yann Pereon; Marguerite Preudhomme; Jean Pouget; Sabrina Sacconi; Guilhem Sole; Tanya Stojkovich; Vincent Tiffreau; Andoni Urtizberea; Christophe Vial; Fabien Zagnoli; Gilbert Caranhac; Claude Bourlier; Gerard Riviere; Alain Geille; Romain K Gherardi; Bruno Eymard; Jack Puymirat; Sandrine Katsahian; Guillaume Bassez
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.